Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Baerbel Schurich"'
Autor:
Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Peter Brossart, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt
Publikováno v:
Haematologica, Vol 101, Iss 12 (2016)
Externí odkaz:
https://doaj.org/article/373bd70facef4c0c81e9f948a298e117
Autor:
Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Ingo G.H. Schmidt-Wolf, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, Hartmut Goldschmidt
Publikováno v:
Haematologica, Vol 100, Iss 7 (2015)
We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone
Externí odkaz:
https://doaj.org/article/7fc4d92e3bbe4aef88595a9e2be8e126
Autor:
Markus Munder, Matthias Zeis, Hartmut Goldschmidt, Anna Jauch, Thomas Hielscher, Elias K. Mai, Mathias Haenel, Christof Scheid, Peter Brossart, Anja Seckinger, Dirk Hose, Maximilian Merz, Jens Hillengass, Christian Gerecke, Hans Walter Lindemann, Baerbel Schurich, Igor Wolfgang Blau, Marc-Steffen Raab, Uta Bertsch, Christina Kunz, Jan Duerig, Hans Salwender, Katja Weisel
Publikováno v:
Haematologica. 101:e485-e487
Up to 20% of patients with multiple myeloma (MM) show signs of peripheral neuropathy (PN) at primary diagnosis.[1][1] Treatment with neurotoxic agents such as bortezomib or thalidomide increases rates of PN in newly diagnosed patients by up to 50%.[2
Autor:
Anja Seckinger, Baerbel Schurich, Uta Bertsch, Ingo G.H. Schmidt-Wolf, Christina Kunz, Mathias Haenel, Dirk Hose, Jan Dürig, Markus Munder, Barbara Huegle-Doerr, Anna Jauch, Igor Wolfgang Blau, Hans Salwender, Christian Gerecke, Jens Hillengass, Maximilian Merz, Thomas Hielscher, Hans-Walter Lindemann, Marc-Steffen Raab, Elias K. Mai, H. Goldschmidt, Katja Weisel, Kai Neben, M. Zeis, Christoph Scheid
Publikováno v:
Leukemia. 29(8)
We aimed at demonstrating non-inferiority of bortezomib/cyclophosphamide/dexamethasone (VCD) compared to bortezomib/doxorubicin/dexamethasone (PAd) induction therapy with respect to very good partial response rates or better (⩾VGPR) in 504 newly di
Autor:
Hans Salwender, Christina Kunz, Hans Walter Lindemann, Jan Duerig, Maximilian Merz, Thomas Hielscher, Markus Munder, Elias K. Mai, Baerbel Schurich, Christof Scheid, Hartmut Goldschmidt, Katja Weisel, Matthias Zeis, Uta Bertsch, Dirk Hose, Ingo G.H. Schmidt-Wolf, Igor Wolfgang Blau, Christian Gerecke, Mathias Hänel
Publikováno v:
Blood. 124:3475-3475
Background: In patients with relapsed multiple myeloma (MM), Moreau and colleagues (Lancet Oncol, 2011) demonstrated that subcutaneous (SC) administration of bortezomib (BTZ) significantly reduced rates of adverse events (AE) compared to the intraven
Autor:
Matthias Zeis, Hans Salwender, Hartmut Goldschmidt, Jan Duerig, Thomas Hielscher, Maximilian Merz, Christof Scheid, Uta Bertsch, Ingo G.H. Schmidt-Wolf, Mathias Haenel, Markus Munder, Baerbel Schurich, Christian Gerecke, Dirk Hose, Christina Kunz, Elias K. Mai, Katja Weisel, Walter Lindemann, Anna Jauch
Publikováno v:
Blood. 124:4777-4777
Background: In the HOVON65/GMMG HD4 trial in patients with newly diagnosed multiple myeloma we have previously shown that patients with renal impairment (RI) (creatinine > 2 mg/dl) have higher response rates and better survival when receiving bortezo
Autor:
Mabast Moohialdin, Hans Salwender, Uta Bertsch, Jan Duerig, Christina Kunz, Thomas Hielscher, Markus Zorn, Mathias Haenel, Igor Wolfgang Blau, Dirk Hose, Baerbel Schurich, Kai Neben, Anja Seckinger, Markus Munder, Walter Lindemann, Matthias Zeis, Christian Gerecke, Ingo GH Schmidt-Wolf, Katja Weisel, Christof Scheid, Hartmut Goldschmidt
Publikováno v:
Blood. 122:1897-1897
Studies in newly diagnosed multiple myeloma (MM) described a prognostic value of the serum free light chain ratio (sFLCr) on progression free survival (PFS) and overall survival (OS). The GMMG MM5 phase III trial compares VCD (bortezomib, cyclophosph
Autor:
Barbara Huegle-Doerr, Kai Neben, Hans Salwender, Markus Munder, Hartmut Goldschmidt, Christina Kunz, Jan Duerig, Thomas Hielscher, Anna Jauch, Ingo G.H. Schmidt-Wolf, Mathias Haenel, Christian Gerecke, Katja Weisel, Walter Lindemann, Maximilian Merz, Igor Wolfgang Blau, Baerbel Schurich, Matthias Zeis, Uta Bertsch, Anja Seckinger, Christof Scheid, Dirk Hose
Publikováno v:
Blood. 122:3369-3369
Background The MM5 phase III trial of the German-Speaking Myeloma Multicenter Group (GMMG) was designed to address two independent primary objectives: 1.) demonstration of non-inferiority of VCD (bortezomib, cyclophosphamide, dexamethasone) induction